Table 2_Cell cycle pathway alterations predict outcomes post-liver transplantation for hep

A prospective single-center study of 91 patients with hepatocellular carcinoma who underwent liver transplantation between 2016 and 2023. Tumor DNA from explanted livers was sequenced for 38 genes, with outcomes including overall survival, recurrence-free survival, and recurrence sites. The dataset was authored by Ashton A. Connor and last updated in April 2026.

Use Cases

• Predicting post-liver transplant survival based on cell cycle pathway alterations mentioned in the description.
• Identifying associations between specific gene mutations and recurrence sites (e.g., liver, lungs).
• Validating molecular biomarkers for hepatocellular carcinoma using the referenced TCGA cohort for comparison.
• Building multivariable models for recurrence-free survival using clinical and genomic variables.

Strengths

• Includes molecular profiling data from targeted sequencing of 38 genes for 91 patients.
• Clinical outcomes are tracked with a median follow-up time of 1,982 days.
• Results are validated against The Cancer Genome Atlas (TCGA) HCC cohort.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data reflects a single-center study, which may limit generalizability.

Provenance

Source

figshare, authored by Ashton A. Connor.

Collection Method

Prospective single-center study with tumor DNA subjected to targeted sequencing.

Time Range

Patients underwent liver transplantation between 11 November 2016 and 4 April 2023.

Freshness

Last updated 2026-04 10 05:59:20; freshness should be verified.

Geography

null